Cargando…

Comorbidities, Cardiovascular Therapies, and COVID-19 Mortality: A Nationwide, Italian Observational Study (ItaliCO)

Background: Italy has one of the world's oldest populations, and suffered one the highest death tolls from Coronavirus disease 2019 (COVID-19) worldwide. Older people with cardiovascular diseases (CVDs), and in particular hypertension, are at higher risk of hospitalization and death for COVID-1...

Descripción completa

Detalles Bibliográficos
Autores principales: Polverino, Francesca, Stern, Debra A., Ruocco, Gaetano, Balestro, Elisabetta, Bassetti, Matteo, Candelli, Marcello, Cirillo, Bruno, Contoli, Marco, Corsico, Angelo, D'Amico, Filippo, D'Elia, Emilia, Falco, Giuseppe, Gasparini, Stefano, Guerra, Stefano, Harari, Sergio, Kraft, Monica, Mennella, Luigi, Papi, Alberto, Parrella, Roberto, Pelosi, Paolo, Poletti, Venerino, Polverino, Mario, Tana, Claudio, Terribile, Roberta, Woods, Jason C., Di Marco, Fabiano, Martinez, Fernando D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7583635/
https://www.ncbi.nlm.nih.gov/pubmed/33195473
http://dx.doi.org/10.3389/fcvm.2020.585866
_version_ 1783599431958921216
author Polverino, Francesca
Stern, Debra A.
Ruocco, Gaetano
Balestro, Elisabetta
Bassetti, Matteo
Candelli, Marcello
Cirillo, Bruno
Contoli, Marco
Corsico, Angelo
D'Amico, Filippo
D'Elia, Emilia
Falco, Giuseppe
Gasparini, Stefano
Guerra, Stefano
Harari, Sergio
Kraft, Monica
Mennella, Luigi
Papi, Alberto
Parrella, Roberto
Pelosi, Paolo
Poletti, Venerino
Polverino, Mario
Tana, Claudio
Terribile, Roberta
Woods, Jason C.
Di Marco, Fabiano
Martinez, Fernando D.
author_facet Polverino, Francesca
Stern, Debra A.
Ruocco, Gaetano
Balestro, Elisabetta
Bassetti, Matteo
Candelli, Marcello
Cirillo, Bruno
Contoli, Marco
Corsico, Angelo
D'Amico, Filippo
D'Elia, Emilia
Falco, Giuseppe
Gasparini, Stefano
Guerra, Stefano
Harari, Sergio
Kraft, Monica
Mennella, Luigi
Papi, Alberto
Parrella, Roberto
Pelosi, Paolo
Poletti, Venerino
Polverino, Mario
Tana, Claudio
Terribile, Roberta
Woods, Jason C.
Di Marco, Fabiano
Martinez, Fernando D.
author_sort Polverino, Francesca
collection PubMed
description Background: Italy has one of the world's oldest populations, and suffered one the highest death tolls from Coronavirus disease 2019 (COVID-19) worldwide. Older people with cardiovascular diseases (CVDs), and in particular hypertension, are at higher risk of hospitalization and death for COVID-19. Whether hypertension medications may increase the risk for death in older COVID 19 inpatients at the highest risk for the disease is currently unknown. Methods: Data from 5,625 COVID-19 inpatients were manually extracted from medical charts from 61 hospitals across Italy. From the initial 5,625 patients, 3,179 were included in the study as they were either discharged or deceased at the time of the data analysis. Primary outcome was inpatient death or recovery. Mixed effects logistic regression models were adjusted for sex, age, and number of comorbidities, with a random effect for site. Results: A large proportion of participating inpatients were ≥65 years old (58%), male (68%), non-smokers (93%) with comorbidities (66%). Each additional comorbidity increased the risk of death by 35% [(adj)OR = 1.35 (1.2, 1.5) p < 0.001]. Use of ACE inhibitors, ARBs, beta-blockers or Ca-antagonists was not associated with significantly increased risk of death. There was a marginal negative association between ARB use and death, and a marginal positive association between diuretic use and death. Conclusions: This Italian nationwide observational study of COVID-19 inpatients, the majority of which ≥65 years old, indicates that there is a linear direct relationship between the number of comorbidities and the risk of death. Among CVDs, hypertension and pre-existing cardiomyopathy were significantly associated with risk of death. The use of hypertension medications reported to be safe in younger cohorts, do not contribute significantly to increased COVID-19 related deaths in an older population that suffered one of the highest death tolls worldwide.
format Online
Article
Text
id pubmed-7583635
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-75836352020-11-13 Comorbidities, Cardiovascular Therapies, and COVID-19 Mortality: A Nationwide, Italian Observational Study (ItaliCO) Polverino, Francesca Stern, Debra A. Ruocco, Gaetano Balestro, Elisabetta Bassetti, Matteo Candelli, Marcello Cirillo, Bruno Contoli, Marco Corsico, Angelo D'Amico, Filippo D'Elia, Emilia Falco, Giuseppe Gasparini, Stefano Guerra, Stefano Harari, Sergio Kraft, Monica Mennella, Luigi Papi, Alberto Parrella, Roberto Pelosi, Paolo Poletti, Venerino Polverino, Mario Tana, Claudio Terribile, Roberta Woods, Jason C. Di Marco, Fabiano Martinez, Fernando D. Front Cardiovasc Med Cardiovascular Medicine Background: Italy has one of the world's oldest populations, and suffered one the highest death tolls from Coronavirus disease 2019 (COVID-19) worldwide. Older people with cardiovascular diseases (CVDs), and in particular hypertension, are at higher risk of hospitalization and death for COVID-19. Whether hypertension medications may increase the risk for death in older COVID 19 inpatients at the highest risk for the disease is currently unknown. Methods: Data from 5,625 COVID-19 inpatients were manually extracted from medical charts from 61 hospitals across Italy. From the initial 5,625 patients, 3,179 were included in the study as they were either discharged or deceased at the time of the data analysis. Primary outcome was inpatient death or recovery. Mixed effects logistic regression models were adjusted for sex, age, and number of comorbidities, with a random effect for site. Results: A large proportion of participating inpatients were ≥65 years old (58%), male (68%), non-smokers (93%) with comorbidities (66%). Each additional comorbidity increased the risk of death by 35% [(adj)OR = 1.35 (1.2, 1.5) p < 0.001]. Use of ACE inhibitors, ARBs, beta-blockers or Ca-antagonists was not associated with significantly increased risk of death. There was a marginal negative association between ARB use and death, and a marginal positive association between diuretic use and death. Conclusions: This Italian nationwide observational study of COVID-19 inpatients, the majority of which ≥65 years old, indicates that there is a linear direct relationship between the number of comorbidities and the risk of death. Among CVDs, hypertension and pre-existing cardiomyopathy were significantly associated with risk of death. The use of hypertension medications reported to be safe in younger cohorts, do not contribute significantly to increased COVID-19 related deaths in an older population that suffered one of the highest death tolls worldwide. Frontiers Media S.A. 2020-10-09 /pmc/articles/PMC7583635/ /pubmed/33195473 http://dx.doi.org/10.3389/fcvm.2020.585866 Text en Copyright © 2020 Polverino, Stern, Ruocco, Balestro, Bassetti, Candelli, Cirillo, Contoli, Corsico, D'Amico, D'Elia, Falco, Gasparini, Guerra, Harari, Kraft, Mennella, Papi, Parrella, Pelosi, Poletti, Polverino, Tana, Terribile, Woods, Di Marco, Martinez and the ItaliCO study group. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cardiovascular Medicine
Polverino, Francesca
Stern, Debra A.
Ruocco, Gaetano
Balestro, Elisabetta
Bassetti, Matteo
Candelli, Marcello
Cirillo, Bruno
Contoli, Marco
Corsico, Angelo
D'Amico, Filippo
D'Elia, Emilia
Falco, Giuseppe
Gasparini, Stefano
Guerra, Stefano
Harari, Sergio
Kraft, Monica
Mennella, Luigi
Papi, Alberto
Parrella, Roberto
Pelosi, Paolo
Poletti, Venerino
Polverino, Mario
Tana, Claudio
Terribile, Roberta
Woods, Jason C.
Di Marco, Fabiano
Martinez, Fernando D.
Comorbidities, Cardiovascular Therapies, and COVID-19 Mortality: A Nationwide, Italian Observational Study (ItaliCO)
title Comorbidities, Cardiovascular Therapies, and COVID-19 Mortality: A Nationwide, Italian Observational Study (ItaliCO)
title_full Comorbidities, Cardiovascular Therapies, and COVID-19 Mortality: A Nationwide, Italian Observational Study (ItaliCO)
title_fullStr Comorbidities, Cardiovascular Therapies, and COVID-19 Mortality: A Nationwide, Italian Observational Study (ItaliCO)
title_full_unstemmed Comorbidities, Cardiovascular Therapies, and COVID-19 Mortality: A Nationwide, Italian Observational Study (ItaliCO)
title_short Comorbidities, Cardiovascular Therapies, and COVID-19 Mortality: A Nationwide, Italian Observational Study (ItaliCO)
title_sort comorbidities, cardiovascular therapies, and covid-19 mortality: a nationwide, italian observational study (italico)
topic Cardiovascular Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7583635/
https://www.ncbi.nlm.nih.gov/pubmed/33195473
http://dx.doi.org/10.3389/fcvm.2020.585866
work_keys_str_mv AT polverinofrancesca comorbiditiescardiovasculartherapiesandcovid19mortalityanationwideitalianobservationalstudyitalico
AT sterndebraa comorbiditiescardiovasculartherapiesandcovid19mortalityanationwideitalianobservationalstudyitalico
AT ruoccogaetano comorbiditiescardiovasculartherapiesandcovid19mortalityanationwideitalianobservationalstudyitalico
AT balestroelisabetta comorbiditiescardiovasculartherapiesandcovid19mortalityanationwideitalianobservationalstudyitalico
AT bassettimatteo comorbiditiescardiovasculartherapiesandcovid19mortalityanationwideitalianobservationalstudyitalico
AT candellimarcello comorbiditiescardiovasculartherapiesandcovid19mortalityanationwideitalianobservationalstudyitalico
AT cirillobruno comorbiditiescardiovasculartherapiesandcovid19mortalityanationwideitalianobservationalstudyitalico
AT contolimarco comorbiditiescardiovasculartherapiesandcovid19mortalityanationwideitalianobservationalstudyitalico
AT corsicoangelo comorbiditiescardiovasculartherapiesandcovid19mortalityanationwideitalianobservationalstudyitalico
AT damicofilippo comorbiditiescardiovasculartherapiesandcovid19mortalityanationwideitalianobservationalstudyitalico
AT deliaemilia comorbiditiescardiovasculartherapiesandcovid19mortalityanationwideitalianobservationalstudyitalico
AT falcogiuseppe comorbiditiescardiovasculartherapiesandcovid19mortalityanationwideitalianobservationalstudyitalico
AT gasparinistefano comorbiditiescardiovasculartherapiesandcovid19mortalityanationwideitalianobservationalstudyitalico
AT guerrastefano comorbiditiescardiovasculartherapiesandcovid19mortalityanationwideitalianobservationalstudyitalico
AT hararisergio comorbiditiescardiovasculartherapiesandcovid19mortalityanationwideitalianobservationalstudyitalico
AT kraftmonica comorbiditiescardiovasculartherapiesandcovid19mortalityanationwideitalianobservationalstudyitalico
AT mennellaluigi comorbiditiescardiovasculartherapiesandcovid19mortalityanationwideitalianobservationalstudyitalico
AT papialberto comorbiditiescardiovasculartherapiesandcovid19mortalityanationwideitalianobservationalstudyitalico
AT parrellaroberto comorbiditiescardiovasculartherapiesandcovid19mortalityanationwideitalianobservationalstudyitalico
AT pelosipaolo comorbiditiescardiovasculartherapiesandcovid19mortalityanationwideitalianobservationalstudyitalico
AT polettivenerino comorbiditiescardiovasculartherapiesandcovid19mortalityanationwideitalianobservationalstudyitalico
AT polverinomario comorbiditiescardiovasculartherapiesandcovid19mortalityanationwideitalianobservationalstudyitalico
AT tanaclaudio comorbiditiescardiovasculartherapiesandcovid19mortalityanationwideitalianobservationalstudyitalico
AT terribileroberta comorbiditiescardiovasculartherapiesandcovid19mortalityanationwideitalianobservationalstudyitalico
AT woodsjasonc comorbiditiescardiovasculartherapiesandcovid19mortalityanationwideitalianobservationalstudyitalico
AT dimarcofabiano comorbiditiescardiovasculartherapiesandcovid19mortalityanationwideitalianobservationalstudyitalico
AT martinezfernandod comorbiditiescardiovasculartherapiesandcovid19mortalityanationwideitalianobservationalstudyitalico
AT comorbiditiescardiovasculartherapiesandcovid19mortalityanationwideitalianobservationalstudyitalico